Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -27.39% is 218% below its 5-year average of 23.18%, near the low end of its 5-year range (-27.39%–39.19%).
As of the fiscal period ended Tuesday, June 30, 2026. 215.08% below its 12-month average of 23.80%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -27.39%.
RETURN ON EQUITY (ROE)
-27.39%
RETURN ON EQUITY (ROE) AVG TTM
23.80%
RETURN ON EQUITY (ROE) AVG 3Y
18.38%
RETURN ON EQUITY (ROE) AVG 5Y
23.18%
RETURN ON EQUITY (ROE) AVG 10Y
22.40%
RETURN ON EQUITY (ROE) AVG 15Y
28.20%
RETURN ON EQUITY (ROE) AVG 20Y
31.71%
CURRENT VS TTM AVG
-215.08%
CURRENT VS 3Y AVG
-249.07%
CURRENT VS 5Y AVG
-218.18%
CURRENT VS 10Y AVG
-222.29%
CURRENT VS 15Y AVG
-197.13%
CURRENT VS 20Y AVG
-186.40%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
-310.55%
vs the sector median at left
Gilead Sciences, Inc.
Market Cap
$179.18B
Return on Equity (ROE)
-27.39%
TTM Avg
23.80%
3Y Avg
18.38%
5Y Avg
23.18%
Market Cap
$180.11B
Return on Equity (ROE)
10.61%
TTM Avg
20.32%
3Y Avg
18.59%
5Y Avg
17.97%
Market Cap
$197.43B
Return on Equity (ROE)
53.50%
TTM Avg
61.58%
3Y Avg
67.05%
5Y Avg
123.42%
Market Cap
$156.82B
Return on Equity (ROE)
5.09%
TTM Avg
9.04%
3Y Avg
13.32%
5Y Avg
16.07%
Market Cap
$206.78B
Return on Equity (ROE)
74.80%
TTM Avg
79.33%
3Y Avg
111.35%
5Y Avg
101.76%
Market Cap
$142.11B
Return on Equity (ROE)
7.61%
TTM Avg
7.38%
3Y Avg
9.51%
5Y Avg
10.24%
Market Cap
$223.93B
Return on Equity (ROE)
13.25%
TTM Avg
12.70%
3Y Avg
13.51%
5Y Avg
15.24%
Market Cap
$131.32B
Return on Equity (ROE)
21.76%
TTM Avg
8.96%
3Y Avg
15.60%
5Y Avg
19.47%
Market Cap
$130.85B
Return on Equity (ROE)
41.59%
TTM Avg
-8.30%
3Y Avg
7.76%
5Y Avg
4.45%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | $179.18B | -27.39% | 23.80% | 18.38% | 23.18% |
| Abbott Laboratories (ABT)vs › | $180.11B | 10.61% | 20.32% | 18.59% | 17.97% |
| Novo Nordisk A/S (NVO)vs › | $197.43B | 53.50% | 61.58% | 67.05% | 123.42% |
| Pfizer Inc. (PFE)vs › | $156.82B | 5.09% | 9.04% | 13.32% | 16.07% |
| Amgen Inc. (AMGN)vs › | $206.78B | 74.80% | 79.33% | 111.35% | 101.76% |
| Danaher Corporation (DHR)vs › | $142.11B | 7.61% | 7.38% | 9.51% | 10.24% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $223.93B | 13.25% | 12.70% | 13.51% | 15.24% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $131.32B | 21.76% | 8.96% | 15.60% | 19.47% |
| Bristol-Myers Squibb Company (BMY)vs › | $130.85B | 41.59% | -8.30% | 7.76% | 4.45% |
| Intuitive Surgical, Inc. (ISRG)vs › | $127.32B | 17.28% | 15.07% | 13.91% | 13.46% |
ROE
-27.4%
ROA
-6.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -27.39% |
| 2026-03-31 | 39.19% |
| 2025-12-31 | 37.49% |
| 2025-09-30 | 37.65% |
| 2025-06-30 | 32.08% |
| 2025-03-31 | 31.13% |
| 2024-12-31 | 2.48% |
| 2024-09-30 | 0.68% |
| 2024-06-30 | 5.76% |
| 2024-03-31 | 2.76% |
| 2023-12-31 | 24.81% |
| 2023-09-30 | 26.33% |
| 2023-06-30 | 25.92% |
| 2023-03-31 | 26.59% |
| 2022-12-31 | 21.62% |
| 2022-09-30 | 15.82% |
| 2022-06-30 | 20.44% |
| 2022-03-31 | 22.66% |
| 2021-12-31 | 29.55% |
| 2021-09-30 | 34.44% |
| 2021-06-30 | 26.20% |
| 2021-03-31 | 1.59% |
| 2020-12-31 | 0.68% |
| 2020-09-30 | 7.27% |
| 2020-06-30 | -1.43% |
| 2020-03-31 | 22.49% |
| 2019-12-31 | 23.91% |
| 2019-09-30 | 13.07% |
| 2019-06-30 | 26.33% |
| 2019-03-31 | 26.84% |
| 2018-12-31 | 25.51% |
| 2018-09-30 | 6.94% |
| 2018-06-30 | 10.19% |
| 2018-03-31 | 16.82% |
| 2017-12-31 | 22.64% |
| 2017-09-30 | 46.69% |
| 2017-06-30 | 53.86% |
| 2017-03-31 | 61.82% |
| 2016-12-31 | 71.48% |
| 2016-09-30 | 89.38% |
| 2016-06-30 | 105.21% |
| 2016-03-31 | 129.43% |
| 2015-12-31 | 97.70% |
| 2015-09-30 | 97.12% |
| 2015-06-30 | 92.36% |
| 2015-03-31 | 82.69% |
| 2014-12-31 | 78.44% |
| 2014-09-30 | 69.33% |
| 2014-06-30 | 46.38% |
| 2014-03-31 | 34.21% |
| 2013-12-31 | 27.04% |
| 2013-09-30 | 27.99% |
| 2013-06-30 | 26.44% |
| 2013-03-31 | 28.29% |
| 2012-12-31 | 27.86% |
| 2012-09-30 | 28.99% |
| 2012-06-30 | 31.99% |
| 2012-03-31 | 35.47% |
| 2011-12-31 | 41.60% |
| 2011-09-30 | 45.25% |
| 2011-06-30 | 45.18% |
| 2011-03-31 | 45.36% |
| 2010-12-31 | 49.48% |
| 2010-09-30 | 53.87% |
| 2010-06-30 | 46.36% |
| 2010-03-31 | 39.52% |
| 2009-12-31 | 41.40% |
| 2009-09-30 | 42.53% |
| 2009-06-30 | 43.02% |
| 2009-03-31 | 43.63% |
| 2008-12-31 | 46.70% |
| 2008-09-30 | 43.90% |
| 2008-06-30 | 45.68% |
| 2008-03-31 | 50.94% |
| 2007-12-31 | 46.69% |
| 2007-09-30 | -15.16% |
| 2007-06-30 | -36.26% |
| 2007-03-31 | -43.87% |
| 2006-12-31 | -65.54% |
| 2006-09-30 | 22.96% |
| 2006-06-30 | 30.92% |
| 2006-03-31 | 27.14% |
| 2005-12-31 | 26.88% |
| 2005-09-30 | 24.54% |
| 2005-06-30 | 24.10% |
| 2005-03-31 | 23.85% |
| 2004-12-31 | 24.02% |
| 2004-09-30 | 38.11% |
| 2004-06-30 | 38.79% |
| 2004-03-31 | 42.44% |
| 2003-12-31 | -7.18% |
| 2003-09-30 | -54.77% |
| 2003-06-30 | -86.07% |
